Ventyx Biosciences, Inc. (VTYX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol VTYX
- Company Ventyx Biosciences, Inc.
- Price $5.81
- Changes Percentage -11.97
- Change -0.79
- Day Low $5.74
- Day High $6.96
- Year High $7.82
- Year Low $0.78
- Market Cap $414,302,490
- Price Avg 50 EMA (D) $3.1
- Price Avg 200 EMA (D) $2.18
- Exchange NASDAQ
- Volume 12,475,428
- Average Volume 3,316,770
- Open $6.71
- Previous Close $6.6
- EPS -1.66
- PE -3.50
- Earnings Announcement 2025-11-06 20:00:00
- Shares Outstanding $71,308,518
Company brief: VENTYX BIOSCIENCES, INC. (VTYX )
- Healthcare
- Biotechnology
- Dr. Raju S. Mohan Ph.D.
- https://www.ventyxbio.com
- US
- N/A
- 10-21-2021
- US92332V1070
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
VTYX Corporation News
Ventyx Biosciences, Inc. (VTYX) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors Transcript
seekingalpha.com -- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Discusses Positive Phase II Results of VTX3232 in Obesity and Cardiovascular Risk Factors October 22, 2025 4:30 PM EDT Company Participants Alex Schwartz Raju M...